{
    "2019-04-10": [
        [
            {
                "time": "2019-04-15",
                "original_text": "Top Stock Reports for Eli Lilly, Altria & Becton Dickinson",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Altria",
                        "Becton Dickinson"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "consumer goods",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-23",
                "original_text": "Lilly Confirms Date and Conference Call for First-Quarter 2019 Financial Results Announcement",
                "features": {
                    "keywords": [
                        "Lilly",
                        "conference call",
                        "financial results"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-16",
                "original_text": "Is AstraZeneca Stock Worth Buying Before Earnings?",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "stock",
                        "earnings"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-18",
                "original_text": "Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice",
                "features": {
                    "keywords": [
                        "growth stock",
                        "Lilly",
                        "solid choice"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-20",
                "original_text": "Why Eli Lilly (LLY) is a Great Dividend Stock Right Now",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "dividend stock"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-25",
                "original_text": "Sanofi sets a fixed price of insulin at $99 per month for some patients",
                "features": {
                    "keywords": [
                        "Sanofi",
                        "insulin",
                        "fixed price"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-27",
                "original_text": "Sanofi to cut U.S. insulin costs for some patients to $99 per month",
                "features": {
                    "keywords": [
                        "Sanofi",
                        "insulin",
                        "costs"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}